For instance, in non-small cell lung cancer, hepatocellular carcinoma, head and neck cancer, gastrointestinal cancer, multiple myeloma, and malignant melanomas NY-ESO-1 tumor expression has been associated with a higher risk of recurrence, poor treatment response and shorter survival (73–83). This evidence concerns the gene CTAG1B and plasma cell myeloma.